CN110898090A - Panax notoginseng flower total saponin and preparation method and application thereof - Google Patents
Panax notoginseng flower total saponin and preparation method and application thereof Download PDFInfo
- Publication number
- CN110898090A CN110898090A CN201911217162.XA CN201911217162A CN110898090A CN 110898090 A CN110898090 A CN 110898090A CN 201911217162 A CN201911217162 A CN 201911217162A CN 110898090 A CN110898090 A CN 110898090A
- Authority
- CN
- China
- Prior art keywords
- panax notoginseng
- ginsenoside
- notoginseng flower
- total saponins
- saponins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 61
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 61
- 229930182490 saponin Natural products 0.000 title claims abstract description 60
- 150000007949 saponins Chemical class 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims description 23
- 235000017709 saponins Nutrition 0.000 claims abstract description 59
- 239000003814 drug Substances 0.000 claims abstract description 11
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 10
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 10
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 claims abstract description 10
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 claims abstract description 10
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000000605 extraction Methods 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 17
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 9
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 9
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 9
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims 1
- XBGLCVZQMWKHFC-UBJQIMRZSA-N Notoginsenoside Fc Natural products O([C@@](CC/C=C(\C)/C)(C)[C@H]1[C@@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@@H]1C(C)(C)[C@@H](O[C@@H]2[C@H](O[C@H]4[C@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O)CO5)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)[C@@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)O1 XBGLCVZQMWKHFC-UBJQIMRZSA-N 0.000 abstract description 10
- XBGLCVZQMWKHFC-UHFFFAOYSA-N notoginsenoside fc Chemical compound C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)CO4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O XBGLCVZQMWKHFC-UHFFFAOYSA-N 0.000 abstract description 10
- 230000007760 free radical scavenging Effects 0.000 abstract description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 abstract description 2
- -1 hydroxyl free radical Chemical class 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 241000628997 Flos Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 244000131316 Panax pseudoginseng Species 0.000 description 4
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000011506 response to oxidative stress Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- HERICYNRBVMDFO-WVYXDZFESA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6s)-6-[(2s)-2-[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-3-[(2r,3r,4s,5s,6r)-3-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)CO5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HERICYNRBVMDFO-WVYXDZFESA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 239000009759 San-Chi Substances 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- NODILNFGTFIURN-USYOXQFSSA-N ginsenoside Rb3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-USYOXQFSSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- PWVJRANWWJJIOF-QVAFKJSISA-N notoginsenoside Fa Natural products CC(=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]3CC[C@]4(C)[C@@H]3[C@H](O)C[C@@H]5[C@@]6(C)CC[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O[C@H]9[C@H](O)OC[C@@H](O)[C@@H]9O)C(C)(C)[C@@H]6CC[C@@]45C)C PWVJRANWWJJIOF-QVAFKJSISA-N 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
Abstract
The invention discloses panax notoginseng flower total saponins and a preparation method and application thereof, belonging to the field of biological medicineExemplary notoginsenoside Fc, ginsenoside Rc and ginsenoside Rb2Ginsenoside Rb3Ginsenoside Rd; the preparation method is carried out at normal temperature, is simple to operate and high in efficiency, and the obtained panax notoginseng flower saponins have strong hydroxyl free radical and DPPH free radical scavenging capacity and can be used for preparing anti-oxidation medicaments.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to panax notoginseng flower total saponins, a preparation method thereof and application thereof in preparing an antioxidant medicine.
Background
Oxidative stress has a very significant influence on human aging and health, and excessive free radicals caused by various factors can initiate and aggravate various diseases, such as alzheimer's disease, cardiovascular diseases, malignant tumors, and the like, so that the application of antioxidants to maintain human health has a wide demand. Because the synthetic antioxidant has the potential risks of carcinogenesis, toxicity and the like, the search for safe, effective and nontoxic natural antioxidants becomes a necessary trend for the development of antioxidants in the current food science, and the plant resources used as both medicine and food also become important raw materials for the development of edible antioxidants.
Notoginseng flower is Panax notoginseng (Burk.) F.H. Chen of Panax of AraliaceaePanax notoginsengDried buds of (Burk.) F.H. Chen are produced mainly in Yunnan province, and have the effects of clearing heat, promoting fluid production, calming liver and lowering blood pressure. At present, the comprehensive utilization research on the pseudo-ginseng flower resources is few, and the pseudo-ginseng flowers are mostly eaten as tea drinks in local places. In 2017, the pseudo-ginseng flowers become local special food in Yunnan province, and a basis is provided for comprehensive utilization of the pseudo-ginseng flowers. The main effective component of the notoginseng flower is reported to be saponin component, the content is about 15 percent, and the notoginseng flower mainly comprises ginsenoside Rb1Ginsenoside Rb2Ginsenoside Rb3Ginsenoside Rc, notoginsenoside Fa, notoginsenoside Fc, etc. Modern pharmacological research shows that the sanchi flower saponin has the functions of tranquilizing, resisting inflammation, protecting liver, lowering blood fat, lowering blood pressure, resisting cancer, etc. and has no report of antioxidant activity.
The method for extracting saponin from notoginseng flower is heating reflux method, immersion method, percolation method, microwave method, etc., but these methods have problems of long extraction time, low efficiency, and loss and change of saponin component due to long-time heating. The ultrahigh pressure extraction technology is a new technology for extracting effective components in plants at normal temperature. Compared with the traditional extraction technology, the ultrahigh pressure extraction technology can shorten the extraction time, reduce the energy consumption and improve the yield of the effective components. At present, the total saponins in the notoginseng flower prepared by adopting an ultrahigh pressure extraction method are not reported in patent documents. Therefore, the invention adopts the notoginseng flower as the raw material, obtains the notoginseng flower saponin after the ultrahigh pressure extraction, and applies the notoginseng flower saponin to the treatment of the diseases related to the oxidative stress reaction.
Disclosure of Invention
The invention aims to provide panax notoginseng flower total saponins, a preparation method thereof and application thereof in preparing antioxidant drugs.
The above object of the present invention is achieved by the following technical solutions:
a flos Notoginseng total saponin contains notoginsenoside Fc, ginsenoside Rc, and ginsenoside Rb at any ratio2Ginsenoside Rb3And ginsenoside Rd, which is found to be a combination of one or more compounds containing dammarane type triterpenoid saponin derivatives shown in the general formula I after analysis:
I
wherein:
R1is 3-O- β -D-xylopyranosyl- (1 → 2) -O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranosyl or 3-O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranosyl;
R2is 20-O- β -D-arabinofuranosyl- (1 → 6) - β -D-glucopyranose, 20-O- β -D-xylopyranosyl- (1 → 6) - β -D-glucopyranose, 20-O- β -D-arabinopyranosyl- (1 → 6) - β -D-glucopyranose or 20-O- β -D-glucopyranose;
when R is1Is 3-O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranose, R2When the compound is 20-O- β -D-arabinofuranosyl- (1 → 6) - β -D-glucopyranose, the compound is ginsenoside Rc;
when R is1Is 3-O- β -D-xylopyranosyl- (1 → 2) -O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranose, R2When the compound is 20-O- β -D-xylopyranosyl- (1 → 6) - β -D-glucopyranose, the compound is notoginsenoside Fc;
when R is1Is 3-O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranose, R2When the compound is 20-O- β -D-arabinopyranosyl- (1 → 6) - β -D-glucopyranose, the compound is ginsenoside Rb2；
When R is1Is 3-O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranose, R2When the compound is 20-O- β -D-xylopyranosyl- (1 → 6) - β -D-glucopyranose, the compound is ginsenoside Rb3；
When R is1Is 3-O- β -D-glucopyranosyl- (1 → 2) - β -D-glucopyranose, R2In the case of 20-O- β -D-glucopyranose, the compound is ginsenoside Rd.
The invention also provides a preparation method of the panax notoginseng flower total saponins, which comprises the following specific steps:
adding an extraction solvent into the notoginseng flower powder, extracting by adopting an ultrahigh pressure extraction method, filtering an extracting solution, concentrating under reduced pressure, and drying to obtain the notoginseng flower total saponins with the saponin content of not less than 50 percent by mass.
The weight volume ratio of the notoginseng flower powder to the extraction solvent is 1: 20-60 g/mL.
The extraction solvent is one or more of water, methanol and ethanol, and is mixed at any ratio.
The pressure of the ultrahigh pressure extraction method is 300-500 MPa; the pressure maintaining time is 3-6 min.
The invention also provides application of the panax notoginseng flower total saponins in preparing an antioxidant drug, and discovers that the panax notoginseng flower total saponins have strong free radical scavenging capacity and can be used as an antioxidant substance to be applied to treatment of diseases related to oxidative stress reaction.
The diseases related to oxidative stress mainly comprise cardiovascular diseases, tumors, skin injuries, hypertension, diabetes and the like.
The antioxidant medicine can be added with a pharmaceutically acceptable carrier, diluent or excipient during preparation.
The medicament dosage form of the antioxidant medicament can be solid preparation or liquid preparation, and mainly comprises tablets, powder, granules, capsules, dripping pills, suppositories, aerosol and the like.
The invention has the advantages that:
1. the preparation method has the advantages of simple operation, short time, low energy consumption and high yield of the effective components of the saponin;
2. the panax notoginseng flower saponins prepared by the invention are natural medicines, have small toxic and side effects, and can be used for treating and preventing diseases related to oxidative stress reaction.
Drawings
FIG. 1 is a high performance liquid chromatogram of total saponins of Panax notoginseng flower.
Detailed Description
The process according to the invention is described in more detail below with reference to the figures and examples, without restricting the scope of the invention to these.
Example 1: the preparation method of the panax notoginseng flower total saponins comprises the following steps:
taking 100g of flos Notoginseng powder, adding 2L of 70% ethanol aqueous solution, extracting at room temperature under 300MPa for 3min under ultrahigh pressure, filtering the extractive solution, concentrating under reduced pressure, and drying to obtain flos Notoginseng total saponin (55.6 g).
The total saponin content is measured by adopting an ultraviolet spectrophotometry, and the specific steps are as follows: precisely absorbing a panax notoginseng total saponin reference solution and a panax notoginseng flower total saponin sample with the same volume into a test tube with a plug, adding 0.2mL of 5% vanillin-glacial acetic acid reagent and 0.8mL perchloric acid after a solvent is volatilized, heating in a water bath at 60 ℃ for 15min, cooling in the ice water bath, adding 5mL glacial acetic acid, shaking up, analyzing by an ultraviolet spectrophotometer, and determining absorbance A at 550 nm; drawing a standard curve of Panax notoginsenosides with absorbance A as abscissa and quality (mg) of reference substance as ordinate, y =244.98x-3.5403 (x: (x = 244.98))R 2=0.9997), the total saponin content is calculated by substituting the absorbance of the sample into a standard curve, and the total saponin content in the panax notoginseng flower is 65.5% by mass.
The method comprises the following steps of (1) measuring each saponin and the content thereof in the panax notoginseng flower total saponins by adopting a high performance liquid chromatography:
taking 5mg of the total saponins of panax notoginseng flowers prepared in the embodiment, dissolving the total saponins of panax notoginseng flowers in 1mL of 50% ethanol solution to prepare a sample solution with the concentration of 5mg/mL, wherein the sample solution is a high performance liquid chromatograph (manufactured by Shimadzu corporation, Japan, including an online degasser DGU-20A3R (C), a binary pump LC-20AB, an automatic sample injector SIL-20A, a column incubator CTO-20A and a detector SPD-20A); chromatographic conditions are as follows: YMC-Triart C18 (4.6 mm × 250mm, 5 μm) chromatographic column, detection wavelength 203nm, flow rate 1mL/min, sample injection amount 20 μ L, column temperature 30 deg.C; mobile phase: water (a) -acetonitrile (B); gradient elution conditions: 0-10min, 25-25% (B); 10-80min, 25-40% (B); 80-90min, 40-60% (B).
The detection result shows that the obtained high performance liquid chromatogram is shown in fig. 1, and the obtained panax notoginseng flower total saponins contain notoginsenoside Fc, ginsenoside Rc and ginsenoside Rb through analysis2Ginsenoside Rb3And the ginsenoside Rd comprises the following components in percentage by mass: the sum of notoginsenoside Fc and ginsenoside Rc, and ginsenoside Rb2Ginsenoside Rb3And the content of ginsenoside Rd is respectively 8.5%, 2.4%, 10.2% and 0.8%.
Example 2: the preparation method of the panax notoginseng flower total saponins comprises the following steps:
adding 6L volume fraction 60% methanol water solution into Notoginseng flower powder 100g, extracting at room temperature under 500MPa for 6min, filtering the extractive solution, concentrating under reduced pressure, and drying to obtain Notoginseng flower total saponin (60.4 g); the content of the saponins in the panax notoginseng flower total saponins is 68.2 percent by mass by adopting the ultraviolet spectrophotometry method which is the same as the embodiment 1.
The detection result of the high performance liquid chromatography determination in the same way as in the example 1 shows that the panax notoginseng flower saponins contain notoginsenoside Fc, ginsenoside Rc and ginsenoside Rb2Ginsenoside Rb3And the ginsenoside Rd comprises the following components in percentage by mass: the sum of notoginsenoside Fc and ginsenoside Rc, and ginsenoside Rb2Ginsenoside Rb3And the content of ginsenoside Rd is respectively 9.1%, 2.6%, 11.8% and 0.9%.
Example 3: the preparation method of the panax notoginseng flower total saponins comprises the following steps:
adding 4L water into 100g flos Notoginseng powder, extracting at room temperature under 400MPa for 4min under ultrahigh pressure, filtering the extractive solution, concentrating under reduced pressure, and drying to obtain flos Notoginseng total saponin (65.3 g); the content of total saponins was 70.2% by mass as determined by the same uv spectrophotometry as in example 1.
The detection result of the high performance liquid chromatography determination in the same way as in the example 1 shows that the panax notoginseng flower saponins contain notoginsenoside Fc, ginsenoside Rc and ginsenoside Rb2Ginsenoside Rb3And the ginsenoside Rd comprises the following components in percentage by mass: the sum of notoginsenoside Fc and ginsenoside Rc, and ginsenoside Rb2Ginsenoside Rb3And the content of ginsenoside Rd is respectively 10.3%, 3.2%, 12.5% and 1.2%.
Example (b): research on antioxidant activity of panax notoginseng flower total saponins
The selected panax notoginseng flower saponins in this example were extracted in example 1.
The experimental method comprises the following steps:
(1) measurement of hydroxyl radical scavenging ability
The sample group comprises 200 μ L of Notoginseng radix total saponin sample and Vc sample with different concentrations and 1.4mL of H with concentration of 6mmol/L2O2Mixing, adding 0.6mL of sodium salicylate with concentration of 20mmol/L and 2mL of ferrous sulfate with concentration of 1.5mmol/L, shaking uniformly, placing in a water bath kettle at 37 ℃ for reaction for 1h, and measuring the light absorption A value at 562nm ultraviolet band;
taking 200 mu L of methanol from the blank group, and reacting according to the method;
taking 200 mu L of a sample to be detected from the background group, and not participating in the reaction;
the hydroxyl radical scavenging capacity is calculated by the following formula:
OH scavenging ability% = (a)Blank space-（ASample (I)-ABackground of the invention））/ ABlank space×100%
(2) DPPH radical scavenging Capacity determination
The sample group is prepared by adding 200 mul of panax notoginseng flower saponins with different concentrations and Vc to-be-detected products into 4mL of 0.1mmol/L DPPH-methanol solution, mixing uniformly, and adding 500 mul of 50mmol/L Tris-HCl solution;
adding 200 mu L of methanol into 4mL of DPPH-methanol solution with the concentration of 0.1mmol/L in the blank group, uniformly mixing, and adding 500 mu L of Tris-HCl solution with the concentration of 50 mmol/L;
taking 200 mu L of a sample to be detected, adding 4mL of methanol solution with the concentration of 0.1mmol/L, uniformly mixing, and adding 500 mu L of Tris-HCl solution with the concentration of 50 mmol/L;
and (3) carrying out a dark reaction on the solutions of each group for 30min, measuring an absorbance A value at a wavelength of 517nm, wherein the DPPH free radical clearance rate formula is as follows:
DPPH radical clearance (%) = aBlank space-（ASample (I)-ABackground of the invention）/ABlank space×100%
The experimental results are as follows:
as shown in tables 1 and 2, the panax notoginseng flower total saponins have strong free radical scavenging ability, the scavenging ability of the panax notoginseng flower total saponins to hydroxyl free radicals and DPPH free radicals is 34.86 percent and 58.18 percent respectively at 100 mug/mL, and the antioxidant ability of the panax notoginseng flower total saponins is enhanced along with the increase of the concentration; and the comparison shows that the panax notoginseng saponins prepared by the invention have antioxidant performance exactly like Vc.
TABLE 1 Elimination of hydroxyl radical by Total Saponin of Panax notoginseng
Claims (7)
1. The panax notoginseng flower total saponins are characterized by containing panax notoginseng saponins Fc, ginsenoside Rc and ginsenoside Rb in any proportion2Ginsenoside Rb3And ginsenoside Rd.
2. A preparation method of panax notoginseng flower total saponins is characterized by comprising the following specific steps:
adding an extraction solvent into the notoginseng flower powder, extracting by adopting an ultrahigh pressure extraction method, filtering an extracting solution, concentrating under reduced pressure, and drying to obtain the notoginseng flower total saponins with the saponin content of not less than 50 percent by mass.
3. The method for preparing panax notoginseng flower total saponins according to claim 1, wherein the weight volume ratio of panax notoginseng flower powder to the extraction solvent is 1: 20-60 g/mL.
4. The method for preparing total saponins of panax notoginseng flower according to claim 1, wherein the extraction solvent is one or more of water, methanol and ethanol mixed at any ratio.
5. The method for preparing panax notoginseng flower total saponins according to claim 1, wherein the pressure of the ultra-high pressure extraction method is 300 to 500 MPa.
6. The method for preparing total saponins of panax notoginseng flower according to claim 1, wherein the pressure maintaining time of the ultra-high pressure extraction method is 3-6 min.
7. The use of the panax notoginseng flower saponins of claim 1 in the preparation of anti-oxidant drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911217162.XA CN110898090A (en) | 2019-12-03 | 2019-12-03 | Panax notoginseng flower total saponin and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911217162.XA CN110898090A (en) | 2019-12-03 | 2019-12-03 | Panax notoginseng flower total saponin and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110898090A true CN110898090A (en) | 2020-03-24 |
Family
ID=69821767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911217162.XA Pending CN110898090A (en) | 2019-12-03 | 2019-12-03 | Panax notoginseng flower total saponin and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110898090A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112521443A (en) * | 2021-01-13 | 2021-03-19 | 昆明理工大学 | Preparation method and application of pseudo-ginseng flower protein |
| CN114984165A (en) * | 2022-06-09 | 2022-09-02 | 昆明理工大学 | Preparation method of saponin compound for treating diabetes based on flos notoginseng extract |
| CN115227731A (en) * | 2021-04-23 | 2022-10-25 | 北京工商大学 | Application of notoginseng flower in regulating and controlling expression of antibacterial peptide and extraction method of notoginseng flower total saponin |
| CN115671152A (en) * | 2021-07-30 | 2023-02-03 | 上海中医药大学附属龙华医院 | Application of panax notoginseng flower saponins in preparation of medicine for preventing and treating acute cerebral infarction |
| CN116731880A (en) * | 2023-06-16 | 2023-09-12 | 昆明理工大学 | Endophytic fungus Mucor multicastus and application thereof |
| CN116832073A (en) * | 2023-06-30 | 2023-10-03 | 金七药业股份有限公司 | Preparation method of pseudo-ginseng flower extract |
-
2019
- 2019-12-03 CN CN201911217162.XA patent/CN110898090A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 谢云峰等: "三七花总皂苷清除活性氧自由基及抗脂质过氧化作用研究", 《国际中医中药杂志》 * |
| 韩建军等: "响应面法对三七总皂苷超高压提取工艺的优化", 《湖北农业科学》 * |
| 魏莉等: "大孔吸附树脂分离纯化三七花蕾总皂苷的研究", 《中药材》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112521443A (en) * | 2021-01-13 | 2021-03-19 | 昆明理工大学 | Preparation method and application of pseudo-ginseng flower protein |
| CN112521443B (en) * | 2021-01-13 | 2024-03-26 | 昆明理工大学 | Preparation method and application of pseudo-ginseng flower protein |
| CN115227731A (en) * | 2021-04-23 | 2022-10-25 | 北京工商大学 | Application of notoginseng flower in regulating and controlling expression of antibacterial peptide and extraction method of notoginseng flower total saponin |
| CN115671152A (en) * | 2021-07-30 | 2023-02-03 | 上海中医药大学附属龙华医院 | Application of panax notoginseng flower saponins in preparation of medicine for preventing and treating acute cerebral infarction |
| CN114984165A (en) * | 2022-06-09 | 2022-09-02 | 昆明理工大学 | Preparation method of saponin compound for treating diabetes based on flos notoginseng extract |
| CN116731880A (en) * | 2023-06-16 | 2023-09-12 | 昆明理工大学 | Endophytic fungus Mucor multicastus and application thereof |
| CN116731880B (en) * | 2023-06-16 | 2024-04-26 | 昆明理工大学 | Endophytic fungus Mucor multicastus and application thereof |
| CN116832073A (en) * | 2023-06-30 | 2023-10-03 | 金七药业股份有限公司 | Preparation method of pseudo-ginseng flower extract |
| CN116832073B (en) * | 2023-06-30 | 2024-01-02 | 金七药业股份有限公司 | Preparation method of pseudo-ginseng flower extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110898090A (en) | Panax notoginseng flower total saponin and preparation method and application thereof | |
| Wu et al. | Toxicity of raw and processed roots of Polygonum multiflorum | |
| Liu et al. | Antioxidant and antitumor activities of the extracts from Chinese yam (Dioscorea opposite Thunb.) flesh and peel and the effective compounds | |
| Nabavi et al. | Biological activities of Juglans regia flowers | |
| Zheng et al. | Composition and serum antioxidation of the main flavonoids from fermented vine tea (Ampelopsis grossedentata) | |
| Qamar et al. | Anticancer and anti-inflammatory perspectives of Pakistan’s indigenous berry Grewia asiatica Linn (Phalsa) | |
| Ma et al. | Chemical components and antioxidant activity of the peels of commercial apple‐shaped pear (fruit of Pyrus pyrifolia cv. pingguoli) | |
| CN102106918A (en) | Method for simultaneously preparing volatile oil, total flavones and total alkaloids from immature bitter oranges | |
| Yang et al. | Kinetic and characterization studies for three bioactive compounds extracted from Rabdosia rubescens using ultrasound | |
| CN107998166A (en) | The preparation method of dandelion extract | |
| CN101485705A (en) | Cooked Panax notoginseng and cooked Panax notoginseng standard extract and application thereof | |
| Tian et al. | Chemical characterization of main bioactive constituents in Paeonia ostii seed meal and GC‐MS analysis of seed oil | |
| Yang et al. | In vitro antioxidant activities and anti-proliferative properties of the functional herb Abrus cantoniensis and its main alkaloid abrine | |
| CN104622865A (en) | Application of ingenane diterpene compound in preparation of antitumor drug | |
| Fu et al. | Purification and antioxidant properties of triterpenic acids from blackened jujube (Ziziphus jujuba Mill.) by macroporous resins | |
| Pujari et al. | Anti-diabetic activity of Physagulin-F isolated from Physalis angulata fruits | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN101973883A (en) | Phenolic compound in tobaccos and preparation method and application thereof | |
| CN104027367A (en) | Method for separating and purifying total polyphenol in redrlowered loropetalum by utilizing macroporous resin | |
| CN110664865A (en) | Method for separating and preparing extract of cinnamon steaming oil residues and application of extract | |
| Shangguan et al. | Response surface methodology-optimized extraction of flavonoids from pomelo peels and isolation of naringin with antioxidant activities by Sephadex LH20 gel chromatography | |
| Wang et al. | Synergistic effects of trans-p-coumaric acid isolated from the ethanol extract of Gynura procumbens in promoting intestinal absorption of chlorogenic acid and reversing alcoholic fatty liver disease | |
| CN109315785A (en) | A kind of green peel of walnut antioxidant and preparation method thereof | |
| CN107320511A (en) | Microwave conversion notoginseng haulm saponin(e prepares method and the application of active component | |
| Al-Areer et al. | Quantitative analysis of total phenolic and flavonoid compounds in different extracts from ginger plant (Zingiber officinale) and evaluation of their anticancer effect against colorectal cancer cell lines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200324 |
|
| RJ01 | Rejection of invention patent application after publication |